The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,653.00
Bid: 1,654.00
Ask: 1,654.50
Change: 12.50 (0.76%)
Spread: 0.50 (0.03%)
Open: 1,638.50
High: 1,655.50
Low: 1,634.00
Prev. Close: 1,640.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Citigroup And Goldman Downgrade Property Firms

Fri, 25th Jan 2019 09:47

LONDON (Alliance News) - The following London-listed shares received analyst recommendations Friday morning and late Thursday:----------FTSE 100----------GOLDMAN RAISES LAND SECURITIES TO 'NEUTRAL' ('SELL') - TARGET 769 (788) PENCE----------CITIGROUP CUTS LAND SECURITIES TO 'SELL' ('NEUTRAL') - TARGET 743 (974) PENCE----------GOLDMAN CUTS BRITISH LAND PRICE TARGET TO 589 (620) PENCE - 'NEUTRAL'----------CITIGROUP CUTS BRITISH LAND TO 'SELL' ('NEUTRAL') - TARGET 452 (647) PENCE----------GOLDMAN CUTS SEGRO PRICE TARGET TO 701 (716) PENCE - 'BUY'----------SOCGEN CUTS ITV TO 'HOLD' ('BUY') - TARGET 138 (190) PENCE----------SHORE CAPITAL RAISES ASTRAZENECA TO 'BUY' ('HOLD')----------HSBC SEES GLAXOSMITHKLINE AS ONE OF THE BEST GLOBAL STOCK IDEAS----------RBC CUTS BHP GROUP PRICE TARGET TO 1500 (1525) PENCE - 'SECTOR PERFORM'----------HSBC RAISES ANGLO AMERICAN PRICE TARGET TO 2120 (2100) PENCE - 'BUY'----------UBS RAISES FRESNILLO TO 'BUY' ('NEUTRAL') - TARGET 1100 (900) PENCE----------JPMORGAN CUTS KINGFISHER PRICE TARGET TO 200 (220) PENCE - 'UNDERWEIGHT'----------GOLDMAN RAISES AB FOODS PRICE TARGET TO 2600 (2500) PENCE - 'NEUTRAL'----------GOLDMAN RAISES SEVERN TRENT PRICE TARGET TO 1847 (1763) PENCE - 'SELL'----------BERNSTEIN CUTS VODAFONE PRICE TARGET TO 225 (235) PENCE - 'OUTPERFORM'----------JPMORGAN CUTS VODAFONE PRICE TARGET TO 230 (240) PENCE - 'OVERWEIGHT'----------DEUTSCHE BANK CUTS ST JAMES'S PLACE PRICE TARGET TO 1070 (1090) PENCE - 'HOLD'----------CREDIT SUISSE CUTS RBS PRICE TARGET TO 280 (295) PENCE - 'NEUTRAL'----------CREDIT SUISSE CUTS LLOYDS PRICE TARGET TO 84 (90) PENCE - 'OUTPERFORM'----------CREDIT SUISSE CUTS BARCLAYS PRICE TARGET TO 190 (210) PENCE - 'NEUTRAL'----------EXANE BNP RAISES HALMA TO 'OUTPERFORM' ('NEUTRAL') - TARGET 1550 (1350) PENCE----------EXANE BNP CUTS SPIRAX-SARCO TO 'UNDERPERFORM' (N) - TARGET 5700 (6300) PENCE----------FTSE 250----------GOLDMAN CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 92 (117) PENCE----------CITIGROUP CUTS INTU PROPERTIES TO 'SELL' ('NEUTRAL') - TARGET 69 (190) PENCE----------CITIGROUP CUTS HAMMERSON TO 'SELL' ('NEUTRAL') - TARGET 278 (465) PENCE----------GOLDMAN CUTS HAMMERSON PRICE TARGET TO 367 (441) PENCE - 'NEUTRAL'----------CITIGROUP CUTS GREAT PORTLAND TO 'SELL' ('NEUTRAL') - TARGET 592 (691) PENCE----------GOLDMAN CUTS GREAT PORTLAND PRICE TARGET TO 633 (662) PENCE - 'NEUTRAL'----------GOLDMAN CUTS DERWENT LONDON PRICE TARGET TO 2960 (2976) PENCE - 'NEUTRAL'----------CITIGROUP CUTS DERWENT LONDON TO 'SELL' ('NEUTRAL') - TARGET 2513 (3186) PENCE----------GOLDMAN CUTS SHAFTESBURY PRICE TARGET TO 748 (806) PENCE - 'SELL'----------CITIGROUP CUTS SHAFTESBURY TO 'NEUTRAL' ('BUY') - TARGET 872 (1229) PENCE----------GOLDMAN CUTS BIG YELLOW GROUP PRICE TARGET TO 972 (993) PENCE - 'NEUTRAL'----------UBS CUTS CAPITAL & COUNTIES PRICE TARGET TO 310 (320) PENCE - 'BUY'----------JPMORGAN CUTS TRAVIS PERKINS PRICE TARGET TO 1330 (1400) PENCE - 'NEUTRAL'----------HSBC INITIATES CRANSWICK WITH 'HOLD' - TARGET 2810 PENCE----------HSBC INITIATES DAIRY CREST GROUP WITH 'BUY' - TARGET 570 PENCE----------HSBC INITIATES GREENCORE WITH 'BUY' - TARGET 270 PENCE----------HSBC INITIATES HILTON FOOD WITH 'HOLD' - TARGET 920 PENCE----------EXANE BNP RAISES PHOENIX GROUP TARGET TO 800 PENCE - 'OUTPERFORM'----------UBS CUTS SOPHOS PRICE TARGET TO 400 (440) PENCE - 'BUY'----------LIBERUM RESUMES RESTAURANT GROUP WITH 'HOLD' - TARGET 180 PENCE----------EXANE BNP CUTS SPECTRIS TO 'NEUTRAL' ('OUTPERFORM') - TARGET 2350 (2550) PENCE----------OTHER MAIN MARKET AND AIM----------CREDIT SUISSE CUTS DAILY MAIL PRICE TARGET TO 685 (770) PENCE - 'NEUTRAL'---------BARCLAYS CUTS DAILY MAIL PRICE TARGET TO 570 (605) PENCE - 'UNDERWEIGHT'----------GOLDMAN CUTS SECURE INCOME REIT PRICE TARGET TO 417 (446) PENCE - 'BUY'----------RBC CUTS FEVERTREE DRINKS PRICE TARGET TO 3400 (3600) PENCE - 'OUTPERFORM'----------DEUTSCHE BANK RAISES FEVERTREE DRINKS TARGET TO 2800 (2700) PENCE - 'HOLD'----------BERENBERG RAISES CONNECT GROUP PRICE TARGET TO 40 (35) PENCE - 'HOLD'----------LIBERUM RESUMES BURFORD CAPITAL WITH 'BUY' - TARGET 2300 PENCE----------

More News
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more
22 Nov 2023 09:48

LONDON BROKER RATINGS: RBC cuts HSBC; Liberum cuts Glencore

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.